382 related articles for article (PubMed ID: 25941618)
1. Tumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunity.
Michaud HA; Eliaou JF; Lafont V; Bonnefoy N; Gros L
Oncoimmunology; 2014 Oct; 3(9):e955684. PubMed ID: 25941618
[TBL] [Abstract][Full Text] [Related]
2. NK cell-based therapeutics for lung cancer.
Pockley AG; Vaupel P; Multhoff G
Expert Opin Biol Ther; 2020 Jan; 20(1):23-33. PubMed ID: 31714156
[No Abstract] [Full Text] [Related]
3. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
Seledtsov VI; Goncharov AG; Seledtsova GV
Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
[TBL] [Abstract][Full Text] [Related]
4. Myeloid cells as effector cells for monoclonal antibody therapy of cancer.
Braster R; O'Toole T; van Egmond M
Methods; 2014 Jan; 65(1):28-37. PubMed ID: 23811299
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the
Chevolet I; Speeckaert R; Schreuer M; Neyns B; Krysko O; Bachert C; Hennart B; Allorge D; van Geel N; Van Gele M; Brochez L
Oncoimmunology; 2015 Mar; 4(3):e982382. PubMed ID: 25949897
[TBL] [Abstract][Full Text] [Related]
6. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.
Kinder M; Greenplate AR; Strohl WR; Jordan RE; Brezski RJ
MAbs; 2015; 7(3):494-504. PubMed ID: 25933349
[TBL] [Abstract][Full Text] [Related]
7. Engineering better immunotherapies via RNA interference.
Sioud M
Hum Vaccin Immunother; 2014; 10(11):3165-74. PubMed ID: 25483669
[TBL] [Abstract][Full Text] [Related]
8. Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell Malignancies.
van der Horst HJ; Nijhof IS; Mutis T; Chamuleau MED
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33086644
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses.
Chen X; Pan X; Zhang W; Guo H; Cheng S; He Q; Yang B; Ding L
Acta Pharm Sin B; 2020 May; 10(5):723-733. PubMed ID: 32528824
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic gene modified cell based cancer vaccines.
Kozłowska A; Mackiewicz J; Mackiewicz A
Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
[TBL] [Abstract][Full Text] [Related]
11. The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs.
Golay J; Taylor RP
Antibodies (Basel); 2020 Oct; 9(4):. PubMed ID: 33126570
[TBL] [Abstract][Full Text] [Related]
12. Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody.
Ha D; Tanaka A; Kibayashi T; Tanemura A; Sugiyama D; Wing JB; Lim EL; Teng KWW; Adeegbe D; Newell EW; Katayama I; Nishikawa H; Sakaguchi S
Proc Natl Acad Sci U S A; 2019 Jan; 116(2):609-618. PubMed ID: 30587582
[TBL] [Abstract][Full Text] [Related]
13. PD-1 blockade at the time of tumor escape potentiates the immune-mediated antitumor effects of a melanoma-targeting monoclonal antibody.
They L; Michaud HA; Becquart O; Lafont V; Guillot B; Boissière-Michot F; Jarlier M; Mollevi C; Eliaou JF; Bonnefoy N; Gros L
Oncoimmunology; 2017; 6(10):e1353857. PubMed ID: 29123966
[TBL] [Abstract][Full Text] [Related]
14. Fc receptor-dependent mechanisms of monoclonal antibody therapy of cancer.
Bakema JE; van Egmond M
Curr Top Microbiol Immunol; 2014; 382():373-92. PubMed ID: 25116109
[TBL] [Abstract][Full Text] [Related]
15. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment.
Rajasekaran N; Chester C; Yonezawa A; Zhao X; Kohrt HE
Immunotargets Ther; 2015; 4():91-100. PubMed ID: 27471715
[TBL] [Abstract][Full Text] [Related]
17. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
18. Harnessing CD16-Mediated NK Cell Functions to Enhance Therapeutic Efficacy of Tumor-Targeting mAbs.
Capuano C; Pighi C; Battella S; De Federicis D; Galandrini R; Palmieri G
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34065399
[TBL] [Abstract][Full Text] [Related]
19. Improving Immunotherapy Against B-Cell Malignancies Using γδ T-Cell-specific Stimulation and Therapeutic Monoclonal Antibodies.
Hoeres T; Pretscher D; Holzmann E; Smetak M; Birkmann J; Triebel J; Bertsch T; Wilhelm M
J Immunother; 2019; 42(9):331-344. PubMed ID: 31318724
[TBL] [Abstract][Full Text] [Related]
20. Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma.
Merli M; Ferrario A; Maffioli M; Arcaini L; Passamonti F
Expert Opin Investig Drugs; 2015; 24(7):897-912. PubMed ID: 25900401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
